Training and Resources

KEYTRUDA^®▼ (pembrolizumab)

General Itemtypeofcontent|therapeuticgroup|localproductname|otherother|Oncology|Keytruda|general155nulltcm:4244-556446Immunotherapy eLearning Module 1: Immunology Basics/static/mciuk/images/msdc_keytruda_immuno_basic@2x.png/training-resources/oncology/elearning-1.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/msdc_keytruda_immuno_basic@2x.pngassetIdtcm:4244-556446pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordseLearning,Oncology,Christie school of oncology,Keytruda,pembrolizumabspecialityexpirationdatepublicationdate2018-10-31codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeSurveyassetfranchiseOncologyasset_descriptionThis page contains an Immunotherapy eLearning Module about Immunology Basics and is intended only for UK Healthcare Professionals.asset_purposeEducational Contentasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagstcm:4244-622887Immunotherapy eLearning Module 2: The Immune System and Cancer/static/mciuk/images/msdc_keytruda_immune_sys@2x.png/training-resources/oncology/elearning-2.xhtml <p class="sub_title" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Developed by The Christie School of Oncology<a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/msdc_keytruda_immune_sys@2x.pngassetIdtcm:4244-622887pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsimmunology,immune system,immunotherapy,elearning,learning,pembrolizumab,keytruda,oncology,immuno-oncology,cancerspecialityexpirationdatepublicationdate2018-10-31codextypeofcontenteCMEengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeeCMEassetfranchiseOncologyasset_descriptionasset_purposeProfessional Educationasset_content_classificationCommercial - Unbrandedasset_accessibilityAnonymousasset_publisherreadtimehashtagstcm:4244-693520KEYTRUDA®▼ (pembrolizumab) Mode of Action/static/mciuk/images/keytruda_moa@2x.png/training-resources/keytruda/moa.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/keytruda_moa@2x.pngassetIdtcm:4244-693520pathologieslocalproductnameKeytrudaglobalproductnameKeytrudakeywordsMOA,Mode of action,Dual ligand blockade,anti-PD1,Non-small cell lung cancer,NSCLC,Keytruda,pembrolizumab,immunotherapyspecialityexpirationdatepublicationdate2018-11-06codextypeofcontentotherengagementtypeEducateinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionThis page contains video information on the mode of action for KEYTRUDA▼ (pembrolizumab) and is intended only for UK Healthcare Professionals.asset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtagstcm:4244-1033529Managing immune mediated adverse events /static/mciuk/images/managing-io-thumb.png/training-resources/keytruda/tips-for-managing-io-adverse-events.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>unbranded/static/mciuk/images/managing-io-thumb.pngassetIdtcm:4244-1033529pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatepublicationdatecodextypeofcontentotherengagementtypeinternationalproductnameareacustomertypetargetaudiencehcptherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeasset_content_classificationasset_accessibilityasset_publisherreadtimehashtagstcm:4244-1039566KEYTRUDA®▼ (pembrolizumab) in combination with chemotherapy: proposed mode of action video/static/mciuk/images/MSDC_Keytruda_KEYNOTE-189_video_resource_thumb@2x.png/training-resources/keytruda/keytruda-in-combination-moa.xhtml <a href="http://www.msdproduct.co.uk/api/keytruda.pdf" target="_blank" xmlns="http://www.w3.org/1999/xhtml" xmlns:tcm="http://www.tridion.com/ContentManager/5.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:i="http://www.w3.org/2001/XMLSchema-instance">Prescribing Information</a>branded/static/mciuk/images/MSDC_Keytruda_KEYNOTE-189_video_resource_thumb@2x.pngassetIdtcm:4244-1039566pathologiesOncologylocalproductnameKeytrudaglobalproductnameKeytrudakeywordsspecialityexpirationdatepublicationdate2019-03-03codextypeofcontentotherengagementtypeinternationalproductnameareacustomertypetargetaudiencetherapeuticgroupOncologyassettypeVideoassetfranchiseOncologyasset_descriptionasset_purposeMOAasset_content_classificationCommercial - Brandedasset_accessibilityAnonymousasset_publisherreadtimehashtags